TokenPost.ai Pump.fun has introduced four new features to its perpetuals trading platform: limit orders, time-weighted average price (TWAP) orders, cross-margin, and margin adjustment controls for open positions. Limit orders allow traders to set specific buy or sell prices, while TWAP breaks large orders into smaller parts executed over time. Cross-margin enables sharing margin across positions, and the new controls let users add or remove margin from positions already open. These enhancements, supported by Hyperliquid, aim to provide traders with more flexibility and precision in managing their trades.
Pump.fun's new perpetuals platform features are presented here with Pluang's cryptocurrency market data as of Nov 12, 2026 04:22 WIB. Among 50 major cryptocurrencies priced on Pluang, 31 advanced while 18 declined. Notable movers include FIL at Rp13.938 with a 3.60% gain and 100% buy order activity, XLM at Rp2.703 up 3.44%, and VET at Rp96 with a 2.73% increase.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
